Lonquex 6 mg Solution for injection in pre-filled syringe (injection)
PDF Leaflet Revision Date: 28 November 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Reduction of neutropenia duration and incidence in chemotherapy patients.
Dosage (summary)
6 mg subcutaneously, 24 hours post-chemotherapy cycle.
Onset of Action / Duration
Onset: 24 hours, Duration: variable
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Avoid in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Cytotoxic chemotherapy
- Lithium
Contraindications
- Hypersensitivity to lipegfilgrastim
Common side effects
- Musculoskeletal pain
- Nausea
- Thrombocytopenia
Counselling Points
- Monitor for allergic reactions
- Report any severe side effects
- Avoid self-administration without training
Serious warnings
- Capillary leak syndrome
- Pulmonary adverse reactions
- Sickle cell crisis
Important Disclaimer
The Lonquex 6 mg Solution for injection in pre-filled syringe (injection) professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
